Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | MDK | P21741 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392233 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL18784372 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL19502532 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24080958 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL14971310 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL25098132 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL22171056 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24046086 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL20942623 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL26877321 | 0.96 | MAPK1 (0.69) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225599-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023003995-A1 | BETA-CATENIN (CTNNB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022256395-A1 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220017902-A1 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2021252523-A2 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021195307-A1 | CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2020132346-A1 | COMBINATION HBV THERAPY | Vir Biotechnology, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017902-A1 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | SERPINC1, SERPINH1, SERPINE1 | MAPK1 4043/4885LGALS3 2107/4885LGALS8 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.